A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
NEJM, 1999 · Multicenter randomized controlled trial in 25 Canadian ICUs (n=838)
Clinical question
Is a restrictive RBC transfusion strategy (transfuse when Hb < 7.0 g/dL) as safe and effective as a liberal strategy (transfuse when Hb < 10.0 g/dL) in critically ill patients?
What the trial found
A restrictive threshold (Hb < 7.0 g/dL) was at least as effective as and potentially superior to a liberal threshold (Hb < 10.0 g/dL) in critically ill patients, cutting blood use by 54%.
Current guideline position
AABB and SCCM clinical practice guidelines strongly recommend a restrictive RBC transfusion threshold (Hb < 7.0 g/dL) in hemodynamically stable critically ill patients.
Clinical interpretation
Foundational trial establishing Hb < 7.0 g/dL as the standard restrictive transfusion trigger in critical care.
Patient-specific RBC transfusion thresholds, current platelet/procedural thresholds, plasma/cryoprecipitate use, and the TRALI vs TACO diagnostic matrix.
The trauma lethal diamond (hypothermia, acidosis, coagulopathy, hypocalcemia), 1:1:1 massive transfusion (PROPPR trial), early TXA (CRASH-2), and TEG/ROTEM algorithms.